Meyerhoff Robert Ryan, Yang Chi-Fu Jeffrey, Speicher Paul J, Gulack Brian C, Hartwig Matthew G, D'Amico Thomas A, Harpole David H, Berry Mark F
Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina; Department of Immunology, Duke University, Durham, North Carolina.
Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
J Surg Res. 2015 Jun 1;196(1):23-32. doi: 10.1016/j.jss.2015.01.043. Epub 2015 Jan 29.
This study was conducted to determine how malignant pleural mesothelioma (MPM) histology was associated with the use of surgery and survival.
Overall survival of patients with stage I-III epithelioid, sarcomatoid, and biphasic MPM in the Surveillance, Epidemiology, and End Results database from 2004-2010 was evaluated using multivariate Cox proportional hazards models.
Of 1183 patients who met inclusion criteria, histologic subtype was epithelioid in 811 patients (69%), biphasic in 148 patients (12%), and sarcomatoid in 224 patients (19%). Median survival was 14 mo in the epithelioid group, 10 mo in the biphasic group, and 4 mo in the sarcomatoid group (P < 0.01). Cancer-directed surgery was used more often in patients with epithelioid (37%, 299/811) and biphasic (44%, 65/148) histologies as compared with patients with sarcomatoid histology (26%, 58/224; P < 0.01). Among patients who underwent surgery, median survival was 19 mo in the epithelioid group, 12 mo in the biphasic group, and 4 mo in the sarcomatoid group (P < 0.01). In multivariate analysis, surgery was associated with improved survival in the epithelioid group (hazard ratio [HR] 0.72; P < 0.01) but not in biphasic (HR 0.73; P = 0.19) or sarcomatoid (HR 0.79; P = 0.18) groups.
Cancer-directed surgery is associated with significantly improved survival for MPM patients with epithelioid histology, but patients with sarcomatoid and biphasic histologies have poor prognoses that may not be favored by operative treatment. The specific histology should be identified before treatment, so that surgery can be offered to patients with epithelioid histology, as these patients are most likely to benefit.
本研究旨在确定恶性胸膜间皮瘤(MPM)的组织学类型与手术应用及生存情况之间的关联。
使用多变量Cox比例风险模型评估2004 - 2010年监测、流行病学和最终结果数据库中I - III期上皮样、肉瘤样和双向性MPM患者的总生存期。
在1183例符合纳入标准的患者中,组织学亚型为上皮样的有811例(69%),双向性的有148例(12%),肉瘤样的有224例(19%)。上皮样组的中位生存期为14个月,双向性组为10个月,肉瘤样组为4个月(P < 0.01)。与肉瘤样组织学类型的患者相比,上皮样(37%,299/811)和双向性(44%,65/148)组织学类型的患者更常接受针对癌症的手术(26%,58/224;P < 0.01)。在接受手术的患者中,上皮样组的中位生存期为19个月,双向性组为12个月,肉瘤样组为4个月(P < 0.01)。在多变量分析中,手术与上皮样组生存期改善相关(风险比[HR] 0.72;P < 0.01),但在双向性组(HR 0.73;P = 0.19)或肉瘤样组(HR 0.79;P = 0.18)中无此关联。
针对癌症的手术与上皮样组织学类型的MPM患者生存期显著改善相关,但肉瘤样和双向性组织学类型的患者预后较差,手术治疗可能对其无益。治疗前应确定具体的组织学类型,以便为上皮样组织学类型的患者提供手术,因为这些患者最可能从中获益。